ReviewCurrent topics in microbiology and immunology2013
Therapeutics against influenza.
Review in Current topics in microbiology and immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Therapeutic Targeting of Viral N-Glycosylation Modification: From Molecular Mechanisms to Clinical Application Prospects.Infectious diseases and therapy · 2025Review
- Characterization of the glycoproteins of fish and amphibian influenza B-like viruses.Science advances · 2025Article
- Research trends and hotspots on global influenza and inflammatory response based on bibliometrics.Virology journal · 2024Review
- Type I Interferon Signaling Increases Versican Expression and Synthesis in Lung Stromal Cells During Influenza Infection.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Article
- Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.Immunity · 2020Article
- The Cranberry Extract OximacroFrontiers in microbiology · 2018Article
- Review
- Progress of small molecular inhibitors in the development of anti-influenza virus agents.Theranostics · 2017Review
- ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity.PLoS biology · 2016Article
- A High Throughput Assay for Screening Host Restriction Factors and Antivirals Targeting Influenza A Virus.Frontiers in microbiology · 2016Article
- Article
- Targeting Importin-α7 as a Therapeutic Approach against Pandemic Influenza Viruses.Journal of virology · 2015Article
- Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.Journal of preventive medicine and hygiene · 2014Review
- A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.The Journal of antimicrobial chemotherapy · 2014Article
- Antigen-activated dendritic cells ameliorate influenza A infections.The Journal of clinical investigation · 2013Article
- The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.The Journal of biological chemistry · 2013Article
- Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite 75 years of research into prevention and treatment of influenza, the viruses that cause this disease continue to rank as some of the most important pathogens afflicting humans today. Progress in development of therapeutics for influenza has been slow for much of that time, but has accelerated in pace over the last two decades. Two classes of antiviral medications are used in humans at present, but each has limitations in scope and effectiveness of use. New strategies involving these licensed agents, including alternate forms of delivery and combination therapy with other drugs, are currently being explored. In addition, several novel antiviral compounds are in various clinical phases of development. Together with strategies designed to target the virus itself, new approaches to interrupt host-pathogen interactions or modulate detrimental aspects of the immune response have been proposed. Therapy for influenza will likely undergo substantial changes in the decades to come, evolving with our knowledge of pathogenesis as new approaches become viable and are validated clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.